Scarica l'app Stockscreener
79.45
1.00%
0.79
Precedente Chiudi:
$78.66
Aprire:
$79.16
Volume 24 ore:
2.49M
Relative Volume:
1.18
Capitalizzazione di mercato:
$12.87B
Reddito:
$705.14M
Utile/perdita netta:
$-453.90M
Rapporto P/E:
-26.13
EPS:
-3.04
Flusso di cassa netto:
$-551.29M
1 W Prestazione:
-1.83%
1M Prestazione:
-6.52%
6M Prestazione:
+33.87%
1 anno Prestazione:
+141.12%
Intervallo 1D:
$77.67
$80.06
Intervallo di 1 settimana:
$77.67
$82.75
Portata 52W:
$23.95
$86.74
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Nome
Ionis Pharmaceuticals Inc
Settore
Industria
Telefono
(760) 931-9200
Indirizzo
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
79.45 | 12.74B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-10-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2025-09-03 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Neutral |
| 2024-08-02 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Ripresa | Jefferies | Buy |
| 2024-06-14 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-23 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Strong Buy |
| 2023-07-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-06-07 | Ripresa | Piper Sandler | Overweight |
| 2023-05-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2022-12-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Ripresa | Morgan Stanley | Overweight |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-31 | Ripresa | Piper Sandler | Overweight |
| 2022-03-01 | Iniziato | Citigroup | Sell |
| 2022-03-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-12-14 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Aggiornamento | UBS | Sell → Neutral |
| 2021-03-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Iniziato | UBS | Sell |
| 2020-12-15 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-09-02 | Iniziato | The Benchmark Company | Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-11-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Reiterato | Stifel | Hold |
| 2018-08-07 | Reiterato | Stifel | Hold |
| 2018-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Ripresa | Goldman | Sell |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-08-09 | Reiterato | Stifel | Hold |
| 2017-03-10 | Downgrade | Goldman | Neutral → Sell |
| 2016-12-28 | Reiterato | BMO Capital Markets | Outperform |
| 2016-12-27 | Reiterato | Leerink Partners | Mkt Perform |
Mostra tutto
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
ARK Investment Management LLC Decreases Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Amova Asset Management Americas Inc. Decreases Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Legato Capital Management LLC Takes Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
HC Wainwright Analysts Raise Earnings Estimates for IONS - MarketBeat
Ionis Pharmaceuticals (IONS) Receives Price Target Raise to $104 by Leerink Partners | IONS Stock News - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $104.00 at Leerink Partners - MarketBeat
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: A Biotech Powerhouse with 15.60% Upside Potential - DirectorsTalk Interviews
Rafferty Asset Management LLC Decreases Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major PlayersAlnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics - Yahoo Finance
FDA Priority Review And 2026 Outlook Might Change The Case For Investing In Ionis (IONS) - Sahm
Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Envestnet Asset Management Inc. - MarketBeat
Ionis Priority Review And DAWNZERA Data Reframe Rare Disease Growth Story - Yahoo Finance
Ionis Pharmaceuticals CEO Teases Late-June Olezarsen Launch After FDA Priority Review Acceptance - Yahoo Finance
Olezarsen Priority Review and Expanding Rare Disease Franchise Could Be A Game Changer For Ionis (IONS) - Yahoo Finance
Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Artisan Partners Limited Partnership - MarketBeat
Ionis FDA And Phase 3 Updates Reframe Rare Disease Valuation Story - Sahm
Ionis Pharmaceuticals (NASDAQ:IONS) Downgraded by Wall Street Zen to Sell - MarketBeat
Ionis Pharmaceuticals Earnings Call Highlights Surging Momentum - TipRanks
Ionis Pharmaceuticals (NASDAQ:IONS) Given New $100.00 Price Target at Piper Sandler - MarketBeat
Ionis Pharmaceuticals (IONS) Target Price Raised to $100 by Pipe - GuruFocus
Ionis presents new data on hereditary angioedema drug at AAAAI By Investing.com - Investing.com India
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amarin (AMRN), Ionis Pharmaceuticals (IONS) and Repligen (RGEN) - The Globe and Mail
Ionis presents new data on hereditary angioedema drug at AAAAI - Investing.com
Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting - Business Wire
TD Asset Management Inc Sells 144,418 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Dana Investment Advisors Inc. Acquires Shares of 18,818 Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (GUTS), Ionis Pharmaceuticals (IONS) and Axsome Therapeutics (AXSM) - The Globe and Mail
Ionis Pharmaceuticals Stock: Digesting Recent Events (NASDAQ:IONS) - Seeking Alpha
Decoding Ionis Pharmaceuticals Inc (IONS): A Strategic SWOT Insi - GuruFocus
Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90 - Bitget
Ionis Q4 Earnings & Sales Beat, Stock Down on Soft 2026 Outlook - The Globe and Mail
Olezarsen sNDA accepted by the FDA for Priority Review - marketscreener.com
IONS: Priority review for olezarsen accelerates launch plans amid robust pipeline and commercial momentum - TradingView
IONS: Priority review for olezarsen and robust pipeline set stage for major growth and global expansion - TradingView
FDA Grants Priority Review to Ionis Pharmaceuticals' Olezarsen A - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $77.00 - MarketBeat
Ionis Pharmaceuticals (IONS) Analyst Rating Update: Stifel Maint - GuruFocus
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2025 Earnings Call Transcript - Insider Monkey
Needham Raises Ionis Pharmaceuticals (IONS) Price Target to $103 - GuruFocus
6 Analysts Have This To Say About Ionis Pharmaceuticals - Benzinga
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG) - Yahoo Finance
Ionis Pharmaceuticals Q4 Loss Of US$229 Million Tests Bullish Profitability Narrative - Sahm
Needham Maintains Buy on Ionis Pharmaceuticals (IONS) Feb 25, 2026 - Meyka
Morgan Stanley raises Ionis Pharmaceuticals price target on strong execution - Investing.com
Ionis Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Ionis Pharmaceuticals Inc (IONS) Q4 2025 Earnings Call Highlight - GuruFocus
Ionis Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
RBC Capital reiterates Ionis Pharmaceuticals stock rating at Outperform By Investing.com - Investing.com South Africa
RBC Capital reiterates Ionis Pharmaceuticals stock rating at Outperform - Investing.com Australia
Earnings call transcript: Ionis Pharmaceuticals Q4 2025 misses EPS forecast, stock drops - Investing.com Australia
Ionis outlines >$2B peak sales target for olezarsen as new launches and pipeline catalysts drive 2026 outlook - MSN
Ionis Pharmaceuticals Inc Azioni (IONS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):